Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 22:12:587801.
doi: 10.3389/fendo.2021.587801. eCollection 2021.

Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit

Sherehan Ibrahim  1 , Jamie R Lowe  2 , Carolyn T Bramante  1 , Surbhi Shah  3 , Nichole R Klatt  4 , Nancy Sherwood  5 , Louis Aronne  6 , Michael Puskarich  7 , Leonardo Tamariz  8 , Ana Palacio  8 , Eric Bomberg  9 , Michael Usher  1 , Samantha King  1 , Brad Benson  1 , Deneen Vojta  10 , Chris Tignanelli  4 , Nicholas Ingraham  11
Affiliations
Review

Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit

Sherehan Ibrahim et al. Front Endocrinol (Lausanne). .

Abstract

Metformin is the first-line medication for type 2 diabetes, but it also has a long history of improved outcomes in infectious diseases, such as influenza, hepatitis C, and in-vitro assays of zika. In the current Covid-19 pandemic, which has rapidly spread throughout the world, 4 observational studies have been published showing reduced mortality among individuals with home metformin use. There are several potential overlapping mechanisms by which metformin may reduce mortality from Covid-19. Metformin's past anti-infectious benefits have been both against the infectious agent directly, as well as by improving the underlying health of the human host. It is unknown if the lower mortality suggested by observational studies in patients infected with Covid-19 who are on home metformin is due to direct activity against the virus itself, improved host substrate, or both.

Keywords: COVID-19; mechanisms of action; metformin; microbiome; obesity.

PubMed Disclaimer

Conflict of interest statement

DV is employed by the company UnitedHealth Group. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Bailey CJ. Metformin: Historical Overview. Diabetologia (2017) 60(9):1566–76. 10.1007/s00125-017-4318-z - DOI - PubMed
    1. G U, L F, SL S. Pharmacological Studies of a New Oral Hypoglycemic Drug. Proc Soc Exp Biol Med (1957) 95:190–2. 10.3181/00379727-95-23163 - DOI - PubMed
    1. Igel LI, Sinha A, Saunders KH, Apovian CM, Vojta D, Aronne LJ. Metformin: An Old Therapy That Deserves a New Indication for the Treatment of Obesity. Curr Atheroscler Rep (2016) 18(4):16. 10.1007/s11883-016-0568-3 - DOI - PubMed
    1. Desilets AR, Dhakal-Karki S, Dunican KC. Role of Metformin for Weight Management in Patients Without Type 2 Diabetes. Ann Pharmacother (2008) 42(6):817–26. 10.1345/aph.1K656 - DOI - PubMed
    1. Valencia WM, Palacio A, Tamariz L, Florez H. Metformin and Ageing: Improving Ageing Outcomes Beyond Glycaemic Control. Diabetologia (2017) 60(9):1630–8. 10.1007/s00125-017-4349-5 - DOI - PMC - PubMed

Publication types